Herpesviruses and Alzheimer’s: Can Antiviral Treatment Help?

Herpesviruses are increasingly mentioned in research on Alzheimer’s disease. This can easily lead to an alarming conclusion: if a person has HSV-1 or has had shingles, does that mean a higher risk of dementia, and should antiviral medication be taken in advance?

The short answer is that a causal link has not been established, and long-term antiviral treatment to prevent Alzheimer’s disease is not standard care. Observational studies nevertheless justify continued research into HSV-1 and VZV as possible risk modifiers. The most important randomized trial found that high-dose valacyclovir did not help people who already had early symptomatic Alzheimer’s disease.

Key points

• HSV-1, VZV and other herpesviruses are not recognized as a universal cause of Alzheimer’s disease.
• Laboratory and epidemiological findings support a hypothesis involving viral reactivation, inflammation and vascular injury, but they do not prove causation.
• In a meta-analysis of observational studies, antiviral treatment of herpesvirus infections was associated with a lower risk of dementia. These studies cannot eliminate the effects of access to care, comorbidities and other confounding factors.
• In the VALAD trial, valacyclovir did not improve cognition or biomarkers in people with early symptomatic Alzheimer’s disease.
• Positive IgG antibodies usually indicate previous exposure, not an active infection of the brain.
• Clinically significant HSV and VZV infections should be treated when medically indicated, but antiviral drugs should not be self-prescribed “for dementia.”

When Alzheimer-related changes begin

Alzheimer’s disease develops gradually. In the Mayo Clinic Study of Aging, which included 2,082 participants, researchers assessed plasma biomarkers, amyloid and tau PET imaging, hippocampal volume and cognitive performance.

At the population level, changes in different measures appeared to accelerate at ages ranging from approximately 48 to 71 years. The authors emphasized that these were cross-sectional data comparing people of different ages, rather than decades-long follow-up of each participant. These age points cannot be used as an individual prediction or as the moment when disease begins.

The practical conclusion is different: there may be a long interval between the beginning of biological changes and the appearance of clear symptoms. Researchers therefore study modifiable risk factors such as blood pressure, diabetes, smoking, physical activity, sleep, hearing, vascular disease and, as one hypothesis, clinically significant infections.

Why herpesviruses are being studied in relation to the brain

After primary infection, herpesviruses remain in the body in a latent state. HSV-1 and VZV can reactivate periodically. Most infected people do not develop dementia, so infection alone cannot explain Alzheimer’s disease.

In laboratory models, HSV-1 has been associated with neuroinflammation and changes in amyloid and tau. Studies of brain tissue have also identified relationships between HHV-6A and HHV-7 signals and molecular networks involved in Alzheimer’s disease. For example, an analysis of independent cohorts published in Neuron supported the biological plausibility of the hypothesis.

Such findings do not establish the direction of the relationship. Viral activity might contribute to inflammation; neurodegeneration and immune aging might make viral reactivation easier; or both processes might occur in parallel. A laboratory model also cannot prove that suppressing a virus will prevent dementia in people.

What observational studies of antiviral treatment show

In registry studies, people with diagnosed HSV or VZV infections who received acyclovir, valacyclovir or other antiherpetic drugs sometimes had a lower subsequent rate of dementia than untreated patients.

A systematic review and meta-analysis of 14 cohorts, involving more than 10 million people aged 50 years or older, reported the following pooled estimates:

• among people with a diagnosed herpesvirus infection, treatment was associated with an approximately 23% lower relative risk of dementia compared with no treatment;
• when all antiherpetic drug users were compared with non-users, the difference was approximately 10%;
• the association was stronger in studies involving more severe HSV or VZV infections.

These are relative rather than absolute figures. If the starting risk is 10%, a 23% relative reduction corresponds to a risk of about 7.7%, or an absolute difference of approximately 2.3 percentage points.

The main limitation is study design. People who receive treatment may seek care earlier, have better access to health services and manage blood pressure, diabetes or other risk factors more effectively. Statistical adjustment reduces but does not remove this confounding. The meta-analysis therefore demonstrates an association, not a proven preventive effect.

What the randomized VALAD trial found

VALAD was a randomized, double-blind trial. It included 120 people with early symptomatic Alzheimer’s disease or mild cognitive impairment, confirmed Alzheimer biomarkers, and antibodies to HSV-1 or HSV-2.

Participants received valacyclovir at a target dose of 4 g per day or placebo for 78 weeks. Deterioration in the primary cognitive outcome was greater in the valacyclovir group. The drug also did not provide benefit in daily functioning, amyloid PET or tau PET measures.

The authors concluded that valacyclovir is not recommended for treating early symptomatic Alzheimer’s disease solely on the basis of HSV seropositivity. The trial was relatively small and had participant dropout, but its results directly argue against using high-dose valacyclovir as an established Alzheimer treatment.

Why prevention and treatment of established disease are different questions

The negative VALAD result does not prove that timely treatment of active shingles or severe HSV infection can never affect long-term risk. The trial treated people in whom Alzheimer pathology was already established.

At the same time, positive associations in registry studies do not show that preventive medication will help healthy people who merely have antibodies. Separate randomized trials would be needed in people without dementia, using clearly defined active infection or high-risk criteria.

What positive IgG antibodies mean

Positive IgG antibodies to HSV-1, VZV, EBV, CMV, HHV-6 or HHV-7 usually indicate that the immune system has encountered the virus in the past. They do not prove active replication, brain involvement or a need for antiviral treatment.

Assessment of possible reactivation depends on the virus and the clinical situation. A clinician considers symptoms, their course, immune status, the affected organ and PCR results from an appropriate specimen. A high IgG value without clinical context is not a reason for prolonged medication.

VZV, shingles and dementia risk

When VZV reactivates, it causes shingles and, in some cases, can affect the nervous system or cerebral blood vessels. These are genuine reasons for timely assessment and treatment, regardless of the Alzheimer hypothesis.

A meta-analysis of observational VZV studies found a small increase in dementia risk after shingles and a lower risk among vaccinated or treated people. The authors noted substantial heterogeneity between studies. These findings do not establish that vaccination or antiviral medication should be prescribed specifically to prevent dementia.

Shingles vaccination should be discussed according to current national recommendations, age and immune status. Its established purpose is to reduce the risk of shingles and its complications.

When urgent medical attention is needed

Urgent assessment is needed if confusion, seizures, a sudden severe headache, limb weakness, facial asymmetry, speech or vision problems, rapidly changing behavior or marked drowsiness occur during or after a herpetic rash. A rash near the eye or on the tip of the nose also requires urgent examination because of the risk of eye involvement.

In these situations, do not wait for routine test results or attempt self-treatment.

What can realistically reduce dementia risk

1. Manage blood pressure, diabetes and cholesterol.
2. Do not smoke and maintain regular physical activity.
3. Treat sleep apnea, chronic insomnia and hearing loss.
4. Maintain social and intellectual activity.
5. Seek timely care for clinically significant HSV and VZV infections.
6. Do not take prolonged courses of valacyclovir, acyclovir or other antivirals without an established indication.

For broader context on biomarkers and risk factors, see “Alzheimer’s Disease: Current Scientific Evidence.”

Frequently asked questions

Can herpes cause Alzheimer’s disease?

A universal causal relationship has not been established. HSV-1 and VZV may be among many risk modifiers, but most infected people do not develop Alzheimer’s disease.

Can valacyclovir be taken to prevent dementia?

There is currently insufficient evidence for this use. Prolonged self-treatment can cause adverse effects, particularly when kidney function is impaired or dosing is inappropriate.

Does valacyclovir help after Alzheimer’s disease has been diagnosed?

In the VALAD trial, high-dose valacyclovir did not improve cognition or neuroimaging markers and is not recommended for this use.

Does a positive IgG result mean a high dementia risk?

No. Positive IgG usually confirms previous exposure. It does not show viral activity in the nervous system or determine an individual’s dementia risk.

Conclusion

The herpesvirus hypothesis remains biologically plausible but unproven. Observational studies associate treatment of clinical HSV and VZV infections with a lower future risk of dementia, while the randomized VALAD trial found no benefit from valacyclovir in established early Alzheimer’s disease.

The balanced practical position is to diagnose and treat active herpesvirus infections when established indications exist. Long-term antiviral therapy should not be prescribed solely because of positive antibodies or fear of dementia.

Key sources

• Hu M et al. Breakpoints in Alzheimer’s disease biomarkers and cognition across the aging spectrum. Alzheimer’s & Dementia. 2026.
• Readhead B et al. Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron. 2018.
• Devanand DP et al. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial. JAMA. 2026.
• Chang ST et al. Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis. Journal of Alzheimer’s Disease. 2026.
• Marra F et al. Effects of herpes zoster infection, antivirals and vaccination on risk of developing dementia. Human Vaccines & Immunotherapeutics. 2025.

Medical disclaimer

This article is for informational purposes and does not replace medical advice. The choice of antiviral medicine, dose and treatment duration depends on the infection, affected site, age, kidney function, immune status and other health conditions.

Author: АС